Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients

Korábbi kezelés

• Alcoholism or drug abuse within one year prior to the screening.
• Suspected hepatocellular carcinoma in B-ultrasound at screening; or fetoprotein alpha was greater than 100ng/ml, or cannot remain stable within 3 months before screening.
• Accepted organ transplantation previously.

Más betegség

• Known allergy to interferon, nucleos(t)ide drugs, or any ingredient of the drug.
• Currently co-infection with HAV, HCV, HDV, HEV, HIV, or any other virus.
• Liver disease caused by other reasons (eg. autoimmune liver disease, alcoholic liver disease, nonalcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.).
• History of serious disease in heart, brain, kidney, retina, muscle, or other major organ and systems.
• Have a history of mental illness or family history of mental illness, or Hamilton Depression Scale score ≥ 7 points.
• Have a history of endocrine system or autoimmune diseases, such as thyroid disease, systemic lupus erythematosus, sarcoidosis, autoimmune thrombocytopenic purpura, psoriasis, etc.
• Chronic diseases requiring long-term treatment, such as uncontrolled hypertension, diabetes, chronic obstructive pulmonary disease, etc.
• Malignant tumor.

Laborértékek

• Neutrophil count<1.5×10\^9/L, hemoglobin<100g/L, or platelet count<80×10\^9/L.
• Serum creatinine was higher than the upper limit of normal at screening.

Egyéb

• Cirrhosis or Child-Pugh score of 7 or above.
• Pregnant or lactating women.
• Other reasons that the investigator considers unsuitable for inclusion.

• Aged between 18 and 65,included.
• HBsAg positive, HBeAg negative, anti HBE antibody positive, HBV-DNA ≥ 2x10\^3 IU/ml, ALT is continuously or repeatedly abnormal, or there is definite inflammation, necrosis and / or fibrosis (≥ G2/S2) confirmed in liver biopsy.
• Received no antiviral treatment previously.
• pregnancy test of Female subjects of childbearing must be negative before the enrollment, and all potential subjects must agree to take effective contraceptive measures during the treatment period and within half a year after the end of the treatment.
• Understand and sign the informed consent voluntarily.